CAR T-Cell Therapy

Expert Recognizes Major Advances in Field During Childhood Cancer Awareness Month

September 26, 2020

In an interview with Targeted Oncology, Tanja Gruber, MD, PhD, discussed the advances she has observed in recent years for the treatment of pediatric patients, including the evolving role of CAR T-cell therapy.

Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma

September 17, 2020

C. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.

CAR T-Cell Data Call for New Strategies in Treatment of Multiple Myeloma

September 15, 2020

During a presentation at the 2020 Society of Hematologic Oncology Virtual Annual Meeting, Andrzej Jakubowiak, MD, PhD, reviewed clinical trials of CAR T-cell therapy in multiple myeloma and the emergence of CAR T cells against SMALF7, GPRC5D, and CD229.

Early Study Shows Feasibility of Single Vector Multiplexed shRNA for CAR T Cells

September 04, 2020

In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple genes in chimeric antigen receptor T cells when used as treatment of patients with cancer.

Clinical Characteristics of DLBCL May Predict Outcomes for Patients Receiving CAR T Cells

August 24, 2020

A single-center experience demonstrated that certain pre- and post-treatment characteristics may predict outcomes for patients with diffuse large B-cell lymphoma following treatment with a chimeric antigen receptor T-cell therapy.

FDA’s Fast Track Designation Granted to Allogeneic CAR Therapy for B-cell Precursor Acute Lymphoblastic Leukemia

August 19, 2020

The FDA has granted a fast track designation to PBCAR0191, a CD19-directed allogeneic chimeric antigen receptor T-cell therapy, for the treatment of patients with advanced B-cell precursor acute lymphoblastic leukemia.

Humanized CD19 CAR T-Cell Therapy Shows Early Promise as Treatment of Hematologic Malignancies

August 18, 2020

An investigator-initiated trial of a humanized CD19-directed chimeric antigen receptor T-cell therapy has been completed, demonstrating the therapy may be a safe and effective treatment for patients with hematologic malignancies.

Ibrutinib May Improve CAR T-Cell Production for Patients With Chronic Lymphocytic Leukemia

August 17, 2020

Ibrutinib during CAR T-cell culture improved the yield and function of CAR T-cell products as treatment of patients with chronic lymphocytic leukemia.

Autologous CAR T-Cell Therapy Induces Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

August 06, 2020

"These data are significant, as they demonstrate that CAR T-cell therapy may be a safe and effective treatment option for patients with Hodgkin lymphoma and potentially other lymphomas expressing the CD30 antigen."

Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point

August 04, 2020

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.